ClinicalTrials.gg
CompletedNCT00971035MOLLYUpdated Nov 29, 2016

A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids

A Phase 2 interventional study of lebrikizumab (MILR1444A) and lebrikizumab (MILR1444A) in Asthma, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-29.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.

Enrollment
8th of 12
210 · median 224
Started
2009
with 1 other
Phase 2
7 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
5 of 12
Genentech, Inc.

Among the 12 studies testing lebrikizumab in Asthma, this one is the 8th largest by enrollment, is one of 2 that started in 2009, is one of 7 in phase 2, and was the 3rd registered.

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing lebrikizumab in Asthma as a file.
02

Study summary

This is a randomized, double-blind, placebo controlled, four-arm, dose-ranging study. The purpose is to evaluate the relationship between the dose of lebrikizumab and the response in terms of the efficacy, safety, and tolerability in patients with asthma who are not on inhaled steroids.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • MILR1444A
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight ≥ 50 kg and ≤ 150 kg at Visit 1
  • Chest radiograph within 12 months of Visit 1 without evidence of a abnormality
  • Stable asthma

Exclusion criteria

Exclusion Criteria:

  • Asthma exacerbation during screening
  • Known
  • Known immunodeficiency
  • Pre-existing lung disease other than asthma
  • Uncontrolled medical disease
  • Current smoker
  • History of substance abuse that may impair or risk the patient's full participation in the study, in the judgment of the investigator
  • Prior allergic reaction to a monoclonal antibody
  • Patients (men and women) of who are not willing to use
  • Pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    A

    Drug: lebrikizumab (MILR1444A)

  • Experimental
    B

    Drug: lebrikizumab (MILR1444A)

  • Experimental
    C

    Drug: lebrikizumab (MILR1444A)

  • Placebo comparator
    D

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in forced expiratory volume in 1 second (FEV1)

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in pre-bronchodilator FEV1

    Time frame: Baseline to Week 24

  2. Change in quality of life and symptom scores

    Time frame: Baseline to Week 12

  3. Change in peak flow

    Time frame: Baseline to Week 1

  4. Rate of asthma exacerbations

    Time frame: During the 24-week treatment period

  5. Change in rescue medication use

    Time frame: From baseline to Week 1

  6. Frequency and severity of adverse events

    Time frame: From the first study-specific procedure through the last observation visit

  7. Incidence of human anti-therapeutic antibodies (ATA)

    Time frame: Baseline to Week 32

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Dec 2010 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2009
First posted
Sep 3, 2009
Start
Nov 2009
Primary completionActual
Dec 2010
CompletionActual
Feb 2011
Results delay requested
Jun 30, 2011
Last update
Nov 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00971035
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Sep 3, 2009
Start date
Nov 2009
Primary completion
Dec 2010
Completion
Feb 2011
Last update
Nov 29, 2016

Study contacts

Michelle Freemer, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion